Click here for more sample CPC practice exam questions with Full Rationale Answers

Practice Exam

Click here for more sample CPC practice exam questions and answers with full rationale

Practice Exam

CPC Practice Exam and Study Guide Package

Practice Exam

What makes a good CPC Practice Exam? Questions and Answers with Full Rationale

CPC Exam Review Video

Laureen shows you her proprietary “Bubbling and Highlighting Technique”

Download your Free copy of my "Medical Coding From Home Ebook" at the top right corner of this page

Practice Exam

2018 CPC Practice Exam Answer Key 150 Questions With Full Rationale (HCPCS, ICD-9-CM, ICD-10, CPT Codes) Click here for more sample CPC practice exam questions with Full Rationale Answers

Practice Exam

Click here for more sample CPC practice exam questions and answers with full rationale

Upcoming HCPCS (DELETED/REVISED) Code Changes Effective from October 1, 2019

Deleted Codes:

J1942 Injection, aripiprazole lauroxil, 1 mg
S1090 Mometasone furoate sinus implant, 370 micrograms

Revised Codes:

J0641 Inj., levoleucovorin, 0.5 mg
J2794 Inj., risperdal consta, 0.5 mg
J7311 Inj., retisert, 0.01 mg
J7313 Inj., iluvien, 0.01 mg
Q4122 Dermacell, awm, porous sq cm
Q4165 Keramatrix, Kerasorb sq cm
Q4184 Cellesta or duo per sq cm


Coding Ahead

Upcoming HCPCS (NEW) Code Changes Effective from October 1, 2019

New Codes:

J0121 Injection, omadacycline, 1 mg
J0122 Injection, eravacycline, 1 mg
J0222 Injection, Patisiran, 0.1 mg
J0291 Injection, plazomicin, 5 mg
J0593 Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
J1096 Dexamethasone, lacrimal ophthalmic insert, 0.1 mg
J1097 phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml
J1303 Injection, ravulizumab-cwvz, 10 mg
J1943 Injection, aripiprazole lauroxil, (aristada initio), 1 mg
J1944 Injection, aripiprazole lauroxil, (aristada), 1 mg
J2798 Injection, risperidone, (perseris), 0.5 mg
J3031 Injection, fremanezumab-vfrm, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
J3111 Injection, romosozumab-aqqg, 1 mg
J7314 Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01 mg
J7331 Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg
J7332 Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg
J7401 Mometasone furoate sinus implant, 10 micrograms
J9118 Injection, calaspargase pegol-mknl, 10 units
J9119 Injection, cemiplimab-rwlc, 1 mg
J9204 Injection, mogamulizumab-kpkc, 1 mg
J9210 Injection, emapalumab-lzsg, 1 mg
J9269 Injection, tagraxofusp-erzs, 10 micrograms
J9313 Injection, moxetumomab pasudotox-tdfk, 0.01 mg
Q4205 Membrane graft or membrane wrap, per square centimeter
Q4206 Fluid flow or fluid GF, 1 cc
Q4208 Novafix, per square cenitmeter
Q4209 Surgraft, per square centimeter
Q4210 Axolotl graft or axolotl dualgraft, per square centimeter
Q4211 Amnion bio or Axobiomembrane, per square centimeter
Q4212 Allogen, per cc
Q4213 Ascent, 0.5 mg
Q4214 Cellesta cord, per square centimeter
Q4215 Axolotl ambient or axolotl cryo, 0.1 mg
Q4216 Artacent cord, per square centimeter
Q4217 Woundfix, BioWound, Woundfix Plus, BioWound Plus, Woundfix Xplus or BioWound Xplus, per square centimeter
Q4218 Surgicord, per square centimeter
Q4219 Surgigraft-dual, per square centimeter
Q4220 BellaCell HD or Surederm, per square centimeter
Q4221 Amniowrap2, per square centimeter
Q4222 Progenamatrix, per square centimeter
Q4226 MyOwn skin, includes harvesting and preparation procedures, per square centimeter
Q5116 Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
Q5117 Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
Q5118 Injection, bevacizumab-bvcr, biosimilar, (Zirabev), 10 mg


Coding Ahead

Upcoming CPT (DELETED) Code Changes Effective from October 1, 2019

Deleted Codes:


0104U Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (32 genes[sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])

90619 Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use


Coding Ahead

Upcoming CPT (NEW) Code Changes Effective from October 1, 2019

New Codes:


0105U Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)
0106U Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion
0107U Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method
0108U Gastroenterology (Barrett’s esophagus), whole slide–digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer
0109U Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species
0110U Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected
0111U Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue
0112U Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene
0113U Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score
0114U Gastroenterology (Barrett’s esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett’s esophagus
0115U Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected
0116U Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications
0117U Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain
0118U Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA
0119U Cardiology, ceramides by liquid chromatography–tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events
0120U Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter
0121U Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood
0122U Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood
0123U Mechanical fragility, RBC, shear stress and spectral analysis profiling
0124U Fetal congenital abnormalities, biochemical assays of 3 analytes (free beta-hCG, PAPP-A, AFP), time-resolved fluorescence immunoassay, maternal dried-blood spot, algorithm reported as risk scores for fetal trisomies 13/18 and 21
0125U Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, maternal serum, algorithm reported as risk scores for fetal trisomies 13/18, 21, and preeclampsia
0126U Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk scores for fetal trisomies 13/18, 21, and preeclampsia
0127U Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia
0128U Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk score for preeclampsia
0129U Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)
0130U Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)
0131U Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)
0132U Hereditary ovarian cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)
0133U Hereditary prostate cancer–related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)
0134U Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)
0135U Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)
0136U ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)
0137U PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)
0138U BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)

See Deleted Codes


Coding Ahead

Changes in Allergy Testing guidelines for Horizon BCBSNJ effective from September 10, 2019


Effective September 10, 2019, Horizon BCBSN will change the way consider certain professional claims for services provided to Horizon BCBSNJ Medicare Advantage (MA) members based on an update to our medical policy, Allergy Testing.

Based on the submitted diagnosis code(s), claims submitted for services provided on and after September 10, 2019 to patients enrolled in Horizon BCBSNJ Medicare Advantage (MA) plans will be processed as follows.

The services represented by CPT code 86003 may be denied as not medically necessary.
Information may be requested to help us determine the medical appropriateness of the services represented by CPT code 86003. Following our review of medical record information, these services may be denied as not medically necessary.

Source: https://www.horizonblue.com/providers/news/news-legal-notices/medical-policy-update-allergy-testing-0


Coding Ahead

Changes in Reimbursement Guidelines for Behavioral Health services


Aetna will no longer allow payment for below mentioned services, Effective from December 1, 2019. 

H2021 — community-based services, per 15 minutes
H0032 — mental health service plan development by non-physician


Coding Ahead

Horizon BCBSNJ Reimbursement Guidelines Changes in Outpatient Laboratory Claims

Outpatient Laboratory Claims: Referring Practitioner Required


In accordance with Centers for Medicare and Medicaid Services (CMS) guidelines, Horizon BCBSNJ requires that claims for clinical laboratory services report the referring practitioner on the claim submission. This applies to participating and non-participating providers.

Effective November 15, 2019 Horizon BCBSNJ will change the way consider and reimburse certain clinical laboratory claims that do not include information about the referring practitioner information. 

Based on the guidelines of this reimbursement policy, Horizon BCBSNJ will deny outpatient claims submitted by participating or nonparticipating clinical laboratories for services provided on and after November 15, 2019 if the referring practitioner information is not included.

To avoid claim outpatient clinical laboratory claim denials, include referring practitioner information as noted below,

  • In 837P transactions please include referring practitioner information in Loop 2310A
  • On CMS  1500 claim forms (per the Medicare Claims Processing Manual Chapter 26 – Completing and Processing Form CMS-1500 Data Set), please include the following referring practitioner information
    •  Field 17.    Enter a “DN” qualifier (to denote Referring Provider), and Enter the referring provider name
    •  Field 17b.   Enter the NPI of the referring provider

To address claims denied for no referring practitioner information, clinical laboratories will have to submit a corrected claim that includes this required information. Until such time as this corrected claim information can be submitted and processed, members cannot be held liable for services related to these claim denials.


Source: https://www.horizonblue.com/providers/news/news-legal-notices/reimbursement-policy-implementation-outpatient-laboratory-claims-referring-practitioner-required


Coding Ahead

Keep on Top of Rapid COVID-19 Funding Changes

Complex coronavirus funding gets even more confusing by the day. If you’re just getting a handle on the three main sources of funding for COVID-19’s impact, get ready for a whole new layer of complications. CARES Act Provider Relief Fund The U.S. Department of Health and Human Services (HHS) is releasing $ 20 billion more in […]

The post Keep on Top of Rapid COVID-19 Funding Changes appeared first on AAPC Knowledge Center.

AAPC Knowledge Center

CMS Announces Changes to Payment Programs

The Centers for Medicare & Medicaid Services (CMS) recently announced that it is reevaluating the amounts that will be paid under its Accelerated Payment Program and suspending its Advance Payment Program to Part B suppliers effective immediately. After a payout of $ 100 billion to healthcare providers and in light of the $ 175 billion recently appropriated […]

The post CMS Announces Changes to Payment Programs appeared first on AAPC Knowledge Center.

AAPC Knowledge Center

COVID-19 Brings Big Changes to Home Health

CARES Act, Medicare interim final rule change who can order home health, homebound definition, and much more. Congress and the Centers for Medicare & Medicaid Services (CMS) have gone into overdrive to provide home care providers with regulatory relief to fight the COVID-19 pandemic. The Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into […]

The post COVID-19 Brings Big Changes to Home Health appeared first on AAPC Knowledge Center.

AAPC Knowledge Center